MXPA05000004A - Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis. - Google Patents

Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis.

Info

Publication number
MXPA05000004A
MXPA05000004A MXPA05000004A MXPA05000004A MXPA05000004A MX PA05000004 A MXPA05000004 A MX PA05000004A MX PA05000004 A MXPA05000004 A MX PA05000004A MX PA05000004 A MXPA05000004 A MX PA05000004A MX PA05000004 A MXPA05000004 A MX PA05000004A
Authority
MX
Mexico
Prior art keywords
description
formula
inhibitors
thiazine
mmp
Prior art date
Application number
MXPA05000004A
Other languages
Spanish (es)
Inventor
Henry Jacobelli
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of MXPA05000004A publication Critical patent/MXPA05000004A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/24—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in positions 2 and 4
    • C07D265/26—Two oxygen atoms, e.g. isatoic anhydride
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/04—1,3-Thiazines; Hydrogenated 1,3-thiazines
    • C07D279/08—1,3-Thiazines; Hydrogenated 1,3-thiazines condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

A compound selected from those of formula (I): wherein: . X1, X2, and X3 represent nitrogen or -CR3 in which R3 represents hydrogen, alkyl, amino, alkylamino, dialkylamino, hydroxy, alkoxy, or halogen, . Gl represents oxygen or S(O)p in which p is from 0 to 2, . G2 represents carbon-carbon triple bond, C=O, C=S, S(O)q in which q is from 0 to 2, or a group of formula (i/a): in which YI and Y2 are as defined in the description, . n is fromO to 6, Zl represents -CR4R5, wherein R4 and R5 are as defined in the description, . A represents 5- or 6-membered monocycle or bicycle aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, . RI represents hydrogen, alkyl, alkenyl, alkynyl, (these groups may be optionally substituted as defined in the description) or the group of formula (i/b): in which s, Z2, B, t and G3 are as defined in the description, and optionally, its optical isomers , N-oxide, and addition salts thereof with a pharmaceutically-acceptable acid or base, and medicinal products containing the same are useful as specific inhibitors of type-13 matrix metalloprotease, for the treatment of i.a arthritis and cancer.
MXPA05000004A 2002-06-25 2003-06-24 Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis. MXPA05000004A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2002/008062 WO2004000321A1 (en) 2002-06-25 2002-06-25 Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis
PCT/EP2003/006601 WO2004000322A1 (en) 2002-06-25 2003-06-24 Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis

Publications (1)

Publication Number Publication Date
MXPA05000004A true MXPA05000004A (en) 2005-04-08

Family

ID=29797117

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05000004A MXPA05000004A (en) 2002-06-25 2003-06-24 Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis.

Country Status (6)

Country Link
JP (1) JP2005538965A (en)
AU (2) AU2002333256A1 (en)
BR (1) BR0312107A (en)
CA (1) CA2491210A1 (en)
MX (1) MXPA05000004A (en)
WO (2) WO2004000321A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8539501A1 (en) 2001-02-14 2002-09-30 Warner Lambert Co TRIAZOLO COMPOUNDS AS MMP INHIBITORS
US6962922B2 (en) 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
AU2003253186A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
JP2006501215A (en) 2002-08-13 2006-01-12 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Monocyclic derivatives as matrix metalloproteinase inhibitors
WO2004014375A2 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Fused bicyclic metalloproteinase inhibitors
PA8578101A1 (en) 2002-08-13 2004-05-07 Warner Lambert Co HETEROBIARILO DERIVATIVES AS METALOPROTEINASE IN MATRIX INHIBITORS
AU2003250470A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidinone fused bicyclic metalloproteinase inhibitors
BR0313724A (en) 2002-08-13 2005-06-28 Warner Lambert Co Azaisoquinoline derivatives as matrix metalloproteinase inhibitors
AU2003253150A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Chromone derivatives as matrix metalloproteinase inhibitors
AU2003250471A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
CN112159347B (en) * 2020-10-27 2022-06-07 常州工程职业技术学院 Preparation method of picolitamide

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6037454B2 (en) * 1976-12-17 1985-08-26 富士写真フイルム株式会社 Heat-developable photosensitive material

Also Published As

Publication number Publication date
JP2005538965A (en) 2005-12-22
CA2491210A1 (en) 2003-12-31
AU2003246574A1 (en) 2004-01-06
BR0312107A (en) 2005-03-29
WO2004000322A1 (en) 2003-12-31
AU2002333256A1 (en) 2004-01-06
WO2004000321A1 (en) 2003-12-31

Similar Documents

Publication Publication Date Title
DE69332002T2 (en) Hydroxyethylaminosulfonamides can be used as inhibitors of retroviral proteases
NZ337861A (en) N-heterocyclic derivatives for treating multiple sclerosis, HIV dementia, Parkinson's disease, meningitis, atherosclerosis, cancer, inflammatory skin diseases
GEP20032869B (en) Alpha -Ketoamide Inhibitors of 20S Proteasome, Pharmaceutical Preparations Containing the Same and Methods for Treatment
MXPA05000004A (en) Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis.
MY136174A (en) Phosphonooxy quinazoline derivatives and their pharmaceutical use
HUP0100669A2 (en) Peptide derivatives as serine protease inhibitors, their use and pharmaceutical compositions comprising thereof
MY119623A (en) Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of benign prostatic hyperplasia
MXPA04008681A (en) Oxo-azabicyclic compounds.
IL173810A0 (en) Imidazopyridine derivatives and pharmaceutical compositions containing the same
MXPA05007494A (en) Novel compounds.
TW368501B (en) 7-(2-aminoethyl)-benzothiazolones
FI935777A0 (en) Inhibitor Foer HIV-Proteas can be used to treat AIDS
IL163625A0 (en) Alkoxy-pyridine derivatives and pharmaceutical compositions containing the same
MXPA04003008A (en) Alkynylated fused ring pyrimidine compounds as matrix metalloprotease-13 inhibitors.
MXPA04009476A (en) (4,2-disubstituted-thiazol-5-yl)amine compounds as pde7 inhibitors.
YU40002A (en) Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
ATE338047T1 (en) NITROGEN BASED CAMPTOTHECIN DERIVATIVES
MXPA03000547A (en) Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder.
IL173895A0 (en) Imidazopyridine derivatives and pharmaceutical compositions containing the same
HUP0003577A2 (en) Tetrahydro gamma-carbolines, process for their preparation, their use and pharmaceutical compositions containing them
ATE247964T1 (en) COMPOUNDS USEFUL AS INHIBITORS OF AICARFT
AU7623796A (en) Azahexane derivatives as substrate isosters of retroviral asparate proteases
GR3022604T3 (en) Inhibitors of hiv protease useful for the treatment of aids.
MXPA04009421A (en) Thiazol-2-yl-imine compounds as pde-7 inhibitors.
AU5390900A (en) Potassium channel blocking agents

Legal Events

Date Code Title Description
FA Abandonment or withdrawal